MX2024012934A - Composiciones terapeuticas con iminoazucares para el tratamiento de enfermedades con acumulacion de heparan sulfato - Google Patents

Composiciones terapeuticas con iminoazucares para el tratamiento de enfermedades con acumulacion de heparan sulfato

Info

Publication number
MX2024012934A
MX2024012934A MX2024012934A MX2024012934A MX2024012934A MX 2024012934 A MX2024012934 A MX 2024012934A MX 2024012934 A MX2024012934 A MX 2024012934A MX 2024012934 A MX2024012934 A MX 2024012934A MX 2024012934 A MX2024012934 A MX 2024012934A
Authority
MX
Mexico
Prior art keywords
heparan sulfate
diseases
accumulation
iminosugars
treatment
Prior art date
Application number
MX2024012934A
Other languages
English (en)
Spanish (es)
Inventor
Luigi Michele Pavone
Annalisa Guaragna
Pasquale Valeria De
Anna Esposito
Massimo D'agostino
Original Assignee
Luigi Michele PAVONE
Annalisa GUARAGNA
Valeria DE PASQUALE
Anna Esposito
Massimo Dagostino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luigi Michele PAVONE, Annalisa GUARAGNA, Valeria DE PASQUALE, Anna Esposito, Massimo Dagostino filed Critical Luigi Michele PAVONE
Publication of MX2024012934A publication Critical patent/MX2024012934A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024012934A 2022-04-20 2024-10-18 Composiciones terapeuticas con iminoazucares para el tratamiento de enfermedades con acumulacion de heparan sulfato MX2024012934A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102022000007808A IT202200007808A1 (it) 2022-04-20 2022-04-20 Composizioni terapeutiche per malattie causate da accumulo di eparan solfato
PCT/EP2023/059966 WO2023203004A1 (en) 2022-04-20 2023-04-18 Therapeutic compositions with imino sugars for the treatment of diseases with accumulation of heparan sulfate

Publications (1)

Publication Number Publication Date
MX2024012934A true MX2024012934A (es) 2024-12-06

Family

ID=82483266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012934A MX2024012934A (es) 2022-04-20 2024-10-18 Composiciones terapeuticas con iminoazucares para el tratamiento de enfermedades con acumulacion de heparan sulfato

Country Status (9)

Country Link
US (1) US20250255856A1 (enExample)
EP (1) EP4511032A1 (enExample)
JP (1) JP2025513384A (enExample)
CN (1) CN119136803A (enExample)
AU (1) AU2023257557A1 (enExample)
CA (1) CA3249619A1 (enExample)
IT (1) IT202200007808A1 (enExample)
MX (1) MX2024012934A (enExample)
WO (1) WO2023203004A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083205C1 (ru) 1994-01-19 1997-07-10 Товарищество с ограниченной ответственностью предприятие "БИОМ" Способ лечения мукополисахаридоза
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002241853A1 (en) 2001-01-12 2002-07-24 Oxford Glycosciences (Uk) Ltd. Mucopolysaccharidosis therapies
JP2003265196A (ja) 2002-03-15 2003-09-24 Seikagaku Kogyo Co Ltd ムコ多糖症のスクリーニング方法
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
KR100762945B1 (ko) 2004-09-08 2007-10-04 진동규 동물 세포주를 이용한 이듀로네이트-설파타제의 발현 방법및 그 발현을 위한 세포주
PL377180A1 (pl) 2005-09-21 2007-04-02 Instytut Farmaceutyczny Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz
US8105788B2 (en) 2005-12-08 2012-01-31 The University Of British Columbia Mucopolysaccharidosis (MPS) diagnostic methods, systems, kits and assays associated therewith
US20070161074A1 (en) 2005-12-27 2007-07-12 Daiichi Pharmaceutical Co., Ltd. Diagnostic method of mucopolysaccharidoses
KR101497194B1 (ko) * 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
AU2010366066B2 (en) 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
WO2012177778A1 (en) 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
HK1221871A1 (zh) * 2013-05-02 2017-06-16 The Chancellor, Masters And Scholars Of The University Of Oxford 使用亚氨基糖进行的糖脂抑制
WO2017201030A1 (en) * 2016-05-16 2017-11-23 Emergent Virology Llc Methods of treating viral infection

Also Published As

Publication number Publication date
AU2023257557A1 (en) 2024-12-05
IT202200007808A1 (it) 2023-10-20
CN119136803A (zh) 2024-12-13
EP4511032A1 (en) 2025-02-26
CA3249619A1 (en) 2023-10-26
US20250255856A1 (en) 2025-08-14
JP2025513384A (ja) 2025-04-24
WO2023203004A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US8058268B2 (en) Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US20250032459A1 (en) Method for treating neurodegenerative diseases
JP6131200B2 (ja) レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
US20240050409A1 (en) Methods and Compositions for Treating Psychotic Disorders
UY28011A1 (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2013534256A5 (enExample)
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20190231768A1 (en) Pridopidine for treating drug induced dyskinesias
CA2816595A1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
IL179160A0 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
JP2022536331A (ja) シヌクレイノパチーの治療
US20240252467A1 (en) Treatment of mental illness via administration of buntanetap and analogues thereof
Wei New approaches to develop drug treatment for Alzheimer’s disease: targeting calcium dysregulation
WO2004012677A3 (en) Methods and compositions to treat conditions associated with neovascularization
JP2014037445A (ja) 抵抗性統合失調症およびその他のｃｎｓ疾患の治療
EP4739309A1 (en) Danegaptide for use in treating synucleinopathies
Ke et al. Remimazolam inhibits chondrocyte senescence and alleviates osteoarthritis: roles and mechanisms
AR132433A1 (es) Derivados de imidazotriazina como moduladores de il-17
Koch et al. Clinically relevant reduction of lamotrigine concentrations by carbamazepine
Li et al. Mechanism of agomelatine alleviating anxiety-and depression-like behaviors in APP/PS1 transgenic mice# br## br